首页> 外文期刊>Metabolism: Clinical and Experimental >Effect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes.
【24h】

Effect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes.

机译:他莫昔芬对HepG2细胞和培养的大鼠肝细胞胆固醇合成的影响。

获取原文
获取原文并翻译 | 示例

摘要

The objective of this study was to investigate the mechanisms by which tamoxifen modifies cholesterol metabolism in cellular models of liver metabolism, HepG2 cells and rat hepatocytes. The effect of tamoxifen on cholesterol and triglyceride-palmitate synthesis was measured using isotopomer spectral analysis (ISA) and gas chromatography-mass spectrometry (GC-MS) and compared with the effects of progesterone, estradiol, the antiestrogen ICI 182,780, and an oxysterol, 25-hydroxycholesterol (25OHC). Cholesterol synthesis in cells incubated in the presence of either [1-(13)C]acetate, [U-13C]glucose, or [4,5-(13)C]mevalonate for 48 hours was reduced in the presence of 10 micromol/L tamoxifen and 12.4 micromol/L 25OHC in both HepG2 cells and rat hepatocytes. The ISA methodology allowed a clear distinction between effects on synthesis and effects on precursor enrichment, and indicated that these compounds did not affect enrichment of the precursors of squalene. Progesterone was effective in both cell types at 30 micromol/L and only in HepG2 cells at 10 micromol/L. Estradiol and ICI 182,780 at 10 micromol/L did not inhibit cholesterol synthesis. None of the compounds altered the synthesis of triglyceride-palmitate in either cell type. Treatment of cells with tamoxifen produced accumulation of three sterol precursors of cholesterol, zymosterol, desmosterol, and delta8 cholesterol. This pattern of precursors indicates inhibition of delta24,25 reduction in addition to the previously described inhibition of delta8 isomerase. We conclude that tamoxifen is an effective inhibitor of the conversion of lanosterol to cholesterol in cellular models at concentrations comparable to those present in the plasma of tamoxifen-treated individuals. Our findings indicate that this mechanism may contribute to the effect of tamoxifen in reducing plasma cholesterol in humans.
机译:这项研究的目的是研究他莫昔芬在肝脏代谢,HepG2细胞和大鼠肝细胞的细胞模型中修饰胆固醇代谢的机制。他莫昔芬对胆固醇和棕榈酸甘油三酯合成的影响是通过同位素同位素分析(ISA)和气相色谱-质谱(GC-MS)测定的,并与孕酮,雌二醇,抗雌激素ICI 182,780和氧固醇的影响进行了比较, 25-羟基胆固醇(25OHC)。在[1-(13)C]乙酸盐,[U-13C]葡萄糖或[4,5-(13)C]甲羟戊酸存在下孵育48小时的细胞中胆固醇的合成减少/ L他莫昔芬和12.4 micromol / L 25OHC在HepG2细胞和大鼠肝细胞中均存在。 ISA方法可以清楚地区分对合成的影响和对前体富集的影响,并表明这些化合物不会影响鲨烯前体的富集。黄体酮对两种细胞类型均有效,浓度为30 micromol / L,仅对HepG2细胞有效,浓度为10 micromol / L。雌二醇和ICI 182,780在10 micromol / L时不会抑制胆固醇的合成。在任何一种细胞类型中,没有一种化合物能改变棕榈酸甘油三酯的合成。用他莫昔芬处理细胞会产生胆固醇,zymosterol,desmosterol和delta8胆固醇的三种固醇前体积聚。除了先前描述的对delta8异构酶的抑制之外,该前体的模式还指示对delta24,25减少的抑制。我们得出的结论是,在与他莫昔芬治疗的个体血浆中存在的浓度相当的浓度下,他莫昔芬是有效的细胞模型中羊毛甾醇向胆固醇转化的抑制剂。我们的发现表明,这种机制可能有助于他莫昔芬在降低人体血浆胆固醇中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号